Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now available as a method of contraception for use in women of reproductive potential with a BMI Twirla® (levonorgestrel and ethinyl ...

TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Limitations of Use Consider ...

PRINCETON, N.J., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that Contraception, an ...

MIAMI, Fla. & NEW YORK -- Noven Pharmaceuticals, Inc., a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc., today announced that it has acquired commercialrights to Minivelle™ (estradiol ...

The FDA has approved Twirla (levonorgestrel and ethinyl estradiol) transdermal system (Agile Therapeutics) as a method of contraception for use in women of reproductive potential with a body mass ...

FDA Previously Assigned PDUFA (Prescription Drug User Fee Act) Goal Date is November 16, 2019 PRINCETON, N.J., June 24, 2019 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women’s ...

Noven announced that CombiPatch (estradiol/norethindrone acetate transdermal system) and Minivelle (estradiol transdermal system) are now readily available following a temporary product shortage.

CHARLESTON, S.C., June 30, 2025 /PRNewswire/ -- Afaxys, Inc., a Public Benefit Corporation and first-of-its kind socially conscious healthcare company focused on serving public health professionals ...

Twirla ® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX) (Agile or the Company), a ...